Rimecor tabs 20mg #30

Instruction for Rimecor

Reed more and buy tablets Rimecor on this page

To buy Rimecor MB just contact us

Composition

1 tablet of Rimecor includes 20 mg of trimetazidine, the active ingredient. Minor ingredients: ludipress, magnesium stearate, aerosil, lactose, sodium croscarmellose. Sheath: polyethylene glycol 4000, titanium dioxide, hydroxypropylmethylcellulose, talc, acid red.
1 tablet of Rimecor MB includes 35 mg of trimetazidine, the active ingredient. Secondary ingredients: methyl methacrylate copolymer, mannitol, microcrystalline cellulose, montan wax, ethyl acrylate, trimethylammonioethyl methacrylate chloride, magnesium stearate. Sheath: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, aluminum varnish (yellow, blue, Ponso 4R).

Form of issue

Rimecor is available in the form of tablets No. 10, 20, 30 or 60.
Rimecor MB is available in the form of tablets with prolonged effect No. 30 or 60.

pharmachologic effect

Antianginal, antihypoxic.

Pharmacodynamics and pharmacokinetics

Rimekor is a drug that under conditions of ischemia improves metabolic processes in neurosensory organs and myocardium. Directly acting on brain neurons and cardiomyocytes, leads to the optimization of their function and metabolism.
Cytoprotective efficiency is caused by an increase in the energy resource, stimulation of oxidative decarboxylation, and increased oxygen consumption, by blocking the oxidative processes of fatty acids and improving aerobic glycolysis.
Trimetazidine beneficially affects myocardial contractility, prevents a decrease in the level of phosphocreatine and ATP inside the cells. When acidosis normalizes the work of ion membrane channels, in cardiomyocytes prevents cumulation of sodium and calcium, helps normalize the content of potassium ions in cells. Reduces the amount of phosphate and intracellular acidosis observed with myocardial ischemia and reperfusion.
Opposes the damaging effect of free radicals, protects the membrane walls of cells, in the field of ischemia inhibits the activation of neutrophils, prolongs the time of the electrical potential, limits the yield of CKK from cells and reduces the severity of myocardial damage of the ischemic nature.
Reduces the number of seizures with angina pectoris, while contributing to a decrease in the intake of nitrates. During the 14 days after admission, there is an increase in the patient's tolerance to physical exertion, as well as a decrease in cases of BP.
On the background of Rimecor therapy, patients notice improvement in hearing and vestibular system, a decrease in the sense of noise in the ears and dizziness. Admission of the drug in the pathology of the eye of vascular genesis leads to the restoration of the functionality of the retina.
When administered orally, most trimetazidine is rapidly absorbed from the digestive tract, reaching a bioavailability of 90%. Plasma Cmax, when taking 20 mg of trimetazidine, is observed after 2 hours and is equal to 55 ng / ml (when taking MB tablets after 3-5 hours and remains at 75% for 24 hours). With plasma proteins binds to 16%, with the achievement in the blood of Css after 60 hours and the volume of distribution - 4.8 l / kg. Passes through the histohematological barriers.
In the form of unchanged drug is excreted by 60% kidneys. T1 / 2 equals 4.5-5 hours (with the taking of MB tablets - 7 hours).
In the elderly (after 65 years) T1 / 2 is higher and is 12 hours. There is a direct dependence of renal clearance with creatinine clearance (CK). With age, hepatic clearance decreases.

Indications for use

The usual indications for the application of Rimecor are:
    sensations of dizziness due to vascular pathologies;
    chorioretinal disorders of a vascular nature;
    cochlear-vestibular disorders of ischemic origin (disruption of the hearing aid, tinnitus, etc.);
    IHD, as a prophylactic against strokes of angina (used in complex treatment).

Contraindications

    pathology of the liver of a serious nature;
    pregnancy;
    hypersensitivity to the composition of the drug;
    breastfeeding;
    kidney pathology (with QC less than 15 ml / min);
    age category up to 18 years.

Side effects

With the reception of Rimecor:
    nausea;
    gastralgia;
    itching;
    vomiting;
    increased heart rate;
    headache.
When taking Rimecor MB:
    nausea;
    stomach ache;
    hives;
    dyspepsia;
    "Tides" to the face;
    vomiting;
    dizziness;
    diarrhea;
    orthostatic hypotension;
    asthenia;
    headache;
    rash and itching of the skin;
    extrapyramidal reversible disorders (akinesia, rigidity, tremor).

Instructions for use Rimecor

Please reed the instruction before buy Rimecor.
Receiving tablets of the drug at 20 mg and MB tablets at 35 mg is indicated (orally) by mouth, in conjunction with a meal.
The dosage of conventional tablets, as a rule, equals 2-3 pieces (40-60 mg) 2-3 times for 24 hours.
The dosage of prolonged tablets, the instruction for the application of Rimecor CF is determined in 1 unit (35 mg) twice (morning and evening) at 24 hours. Doubling the number of tablets, with a single dose, should not be.
The duration of use of both these and other tablets depends on the observed disease and is prescribed by the doctor.

Overdose

The described facts of overdose by Rimecor are small and unreliable. Treatment, in such cases, should be reduced to symptomatic therapy.

Interaction

The interaction of Rimecor with other drugs is not described.

Storage conditions

Storage temperature should be within 15-25 ° C.

Shelf life

Conventional tablets are preserved for 36 months, MB tablets for 24 months.

special instructions

Rimecor is not used to level attacks of angina pectoris, at the beginning of hospitalization, for the main course of treatment for unstable angina, and myocardial infarction.
In the prevention of angina attacks, in the case of their further development, changes in the therapy should be made.

Children

Rimecor is not used in the treatment of patients under 18 years of age.

In pregnancy and lactation

The use of Rimecor is contraindicated during periods of breastfeeding and pregnancy.

Reviews

Feedback about Rimecor, both in principle and about all trimetazidine preparations, are often positive. Both the patients themselves and the doctors prescribing it highly appreciate the rapid effect of the drug and, importantly, a rather small list of possible side effects, which, among other things, are quite rare and are weakly expressed. In particular, the effectiveness of the drug is assessed with dizziness and tinnitus, which does not prevent it from showing excellent results of therapy and with other indications.